Export financials
IDEXX Laboratories (IDXX)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.

IDEXX Laboratories Financial Ratios 2025-2007 | IDXX
Brief overview of IDEXX Laboratories's financial ratios
Ratios are assessed across five available annual reports in the 2021–2025 interval.
The latest available valuation ratios are P/E 48.25x (median 56.14x), EV/EBITDA 45.27x (median 39.53x), P/S 11.88x (median 12.7x). Current valuation broadly matches recent historical reference points; the difference from five-year medians is -6.5%.
Current earnings relative to valuation equal about 2.1% on the 1/P/E measure. This is a valuation reference, not an expected payout.
The latest available business-quality ratios are ROE 66%, ROA 31.6%, ROCE 61.8%. Profitability forms a strong profile, with capital and assets producing substantial returns.
Current PEG of 3.06x points to a premium over forecast earnings momentum.
The cash conversion cycle lengthened from 90.5 days to 102.9 days, or 12.4 days. More cash is tied up in operations.
What the ratios show
IDEXX Laboratories's market valuation is near its own historical norm, while quality ratios provide no extreme signal.
Annual Financial Ratios IDEXX Laboratories
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 48.3 | 42.4 | 56.1 | 63.0 | 60.9 | 76.3 | 57.1 | 47.8 | 62.2 | 48.7 | 33.8 | 43.6 | 32.2 | 29.7 | 29.7 | 12.7 | 10.5 | 12.9 | - | |
P/S |
11.9 | 9.7 | 13.0 | 12.7 | 14.1 | 16.4 | 10.2 | 8.2 | 8.3 | 6.1 | 4.1 | 5.3 | 4.4 | 4.1 | 3.9 | - | - | - | - |
EPS |
13.2 | 10.8 | 10.2 | 8.1 | 8.7 | 6.8 | 5.0 | 4.3 | 3 | 2.5 | 2.1 | 1.8 | 1.8 | 3.2 | 2.9 | 2.5 | 2.1 | 1.9 | - |
EV (Enterprise Value) |
52.7 B | 39.1 B | 48.8 B | 44.8 B | 47 B | 45.7 B | 26 B | 19.5 B | 18 B | 12.3 B | 7.93 B | 8.87 B | 6.48 B | 5.53 B | 5.12 B | 1.96 B | 1.48 B | 1.42 B | -60.4 M |
EBITDA per Share |
18.7 | 15.3 | 14.6 | 12.1 | 12.2 | 9.26 | 7.44 | 6.61 | 5.65 | 4.77 | 4.07 | 3.19 | 3.02 | 2.86 | 2.5 | 4.33 | 3.84 | 3.68 | - |
EV/EBITDA |
35.0 | 31.0 | 40.2 | 44.3 | 45.3 | 57.8 | 39.5 | 32.9 | 35.2 | 27.7 | 20.0 | 26.6 | 18.4 | 16.1 | 16.3 | 7.9 | 6.5 | 6.4 | - |
PEG |
3.06 | 2.64 | 3.18 | 3.72 | 2.93 | 4.26 | 3.94 | 1.07 | 2.9 | 2.52 | 2.41 | 15.39 | 3.6 | 2.17 | 1.82 | - | - | - | - |
P/B |
31.8 | 23.6 | 32.0 | 70.3 | 65.7 | 70.2 | 137.4 | -1953.9 | -304.2 | -99.9 | -77.3 | 67.4 | 11.7 | 8.3 | 8.9 | 3.1 | 2.5 | - | - |
P/CF |
43.3 | 40.5 | 52.3 | 78.8 | 60.0 | 68.5 | 80.4 | 65.1 | 55.2 | 40.1 | 48.7 | 45.3 | 36.1 | 32.3 | 28.8 | 10.1 | 7.4 | 10.4 | - |
ROE % |
65.99 | 55.65 | 56.92 | 111.56 | 107.95 | 92.04 | 240.53 | -4083.52 | -488.73 | -205.19 | -228.68 | 154.70 | 36.24 | 28.02 | 29.98 | 24.60 | 23.75 | 26.51 | - |
ROA % |
31.62 | 26.96 | 25.92 | 24.72 | 30.56 | 25.35 | 23.34 | 24.52 | 15.36 | 14.51 | 13.02 | 13.14 | 15.26 | 16.15 | 15.69 | 15.75 | 15.12 | - | - |
ROCE % |
61.76 | 50.70 | 47.53 | 59.48 | 55.69 | 40.59 | 49.93 | 64.07 | 58.27 | 58.75 | 49.84 | 46.20 | 35.47 | 37.66 | 39.77 | 33.31 | 31.87 | 39.36 | - |
Current Ratio |
1.9 | 1.9 | 1.8 | 1.3 | 1.4 | 1.4 | 0.9 | 0.8 | 1.0 | 0.9 | 1.0 | 0.9 | 1.4 | 1.4 | 1.2 | 2.8 | 2.8 | - | - |
DSO |
43.5 | 43.6 | 42.8 | 41.7 | 39.7 | 40.5 | 46.6 | 45.0 | 50.1 | 47.7 | 45.6 | 44.5 | 41.9 | 39.0 | 42.3 | - | - | - | - |
DIO |
84.3 | 91.6 | 92.8 | 85.3 | 65.9 | 65.1 | 68.4 | 65.1 | 68.8 | 72.1 | 96.9 | 87.4 | 78.4 | 86.6 | 84.9 | 82.9 | - | - | - |
DPO |
24.9 | 27.0 | 27.4 | 23.4 | 26.2 | 23.6 | 25.3 | 26.1 | 28.0 | 27.4 | 27.0 | 24.4 | 17.6 | 21.7 | 23.3 | 14.5 | 6.9 | - | - |
Operating Cycle |
127.8 | 135.2 | 135.6 | 127.0 | 105.6 | 105.6 | 115.0 | 110.1 | 118.9 | 119.8 | 142.5 | 131.9 | 120.3 | 125.6 | 127.2 | 82.9 | - | - | - |
Cash Conversion Cycle |
102.9 | 108.2 | 108.2 | 103.6 | 79.4 | 82.0 | 89.7 | 83.9 | 90.8 | 92.4 | 115.4 | 107.5 | 102.7 | 103.9 | 103.9 | 68.3 | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Financial Ratios IDEXX Laboratories
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q4 | 2010-Q3 | 2010-Q2 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
4.02 | 4.29 | 3.5 | 3.1099999999999994 | 3.43 | 3.66 | 2.98 | 2.6500000000000004 | 2.83 | 2.46 | 2.84 | 2.34 | 2.55 | 2.7 | 2.58 | 2.079999999999999 | 2.17 | 1.57 | 2.3 | 1.92 | 2.06 | 2.37 | 2.39 | 2.0500000000000007 | 1.71 | 1.75 | 1.31 | 1.05 | 1.26 | 1.46 | 1.19 | 0.99 | 1.07 | 1.25 | 1.02 | 0.44 | 0.81 | 0.97 | 0.78 | 0.59 | 0.63 | 0.75 | 0.51 | 0.49 | 0.48 | 0.61 | 0.49 | 0.27 | 0.52 | 0.56 | 0.45 | 0.83 | 0.87 | 1.01 | 0.82 | 0.79 | 0.78 | 0.93 | 0.74 | 0.68 | 0.68 | 0.85 | 0.64 | 0.63 | 0.6 | 0.64 |
EBITDA per Share |
5.1 | 6.39 | 5.03 | -1.77 K | 4.89 | 4.64 | 4.31 | -1.26 K | 4.11 | 3.19 | 3.96 | 21.7 K | 3.66 | 3.9 | 3.72 | -683 | 3.28 | 2.47 | 3.26 | -1.08 K | 2.97 | 3.34 | 3.19 | 2.52 | 2.3 | 2.55 | 1.96 | -655 | 1.88 | 2.16 | 1.79 | 1.34 | 2.07 | 1.91 | 1.53 | -393 | 1.38 | 1.63 | 1.28 | -237 | 1.2 | 1.38 | 1.03 | -44 | 0.98 | 1.13 | 0.94 | -0.64 | 0.88 | 0.96 | 1.62 | 0.57 | 1.51 | 1.73 | 1.37 | -390 | 1.38 | 1.61 | 1.32 | -81.5 | 1.2 | 1.45 | 1.13 | -591 | 1.06 | 1.34 |
ROE % |
71.31 | 71.93 | 71.10 | 69.96 | 68.05 | 64.85 | 57.56 | 55.82 | 55.37 | 57.34 | 64.98 | 75.41 | 90.60 | 112.25 | 120.63 | 125.50 | 120.80 | 105.97 | 104.17 | 102.90 | 106.96 | 116.94 | 144.36 | 218.83 | 242.08 | 262.59 | 281.37 | 375.87 | -602.55 | -1636.48 | -1975.81 | -2356.49 | -1500.02 | -665.49 | -498.63 | -409.39 | -386.73 | -138.35 | -830.01 | -798.95 | -803.35 | -1020.00 | 436.71 | 635.76 | 710.63 | 847.35 | 194.12 | 66.54 | 52.81 | 38.62 | 35.81 | 33.82 | 32.29 | 30.69 | 29.56 | 29.64 | 29.87 | 29.50 | 28.79 | 27.74 | 27.03 | 26.81 | 25.91 | 6.33 | 6.35 | 7.09 |
ROA % |
34.02 | 33.57 | 32.57 | 31.89 | 31.05 | 29.89 | 27.02 | 26.49 | 25.89 | 25.82 | 27.68 | 28.28 | 28.58 | 28.56 | 25.81 | 25.67 | 26.08 | 26.56 | 29.90 | 31.20 | 32.14 | 31.95 | 31.15 | 28.30 | 25.61 | 24.68 | 24.37 | 24.55 | 25.18 | 25.04 | 24.89 | 24.87 | 21.53 | 19.69 | 17.76 | 16.07 | 17.25 | 16.79 | 16.09 | 14.81 | 14.39 | 13.63 | 12.97 | 13.11 | 11.98 | 13.03 | 13.63 | 14.07 | 15.71 | 15.49 | 15.67 | 15.94 | 16.35 | 16.45 | 16.62 | 16.50 | 16.26 | 16.31 | 16.62 | 16.80 | 17.17 | 17.22 | 16.57 | 4.05 | 4.03 | 4.46 |
ROCE % |
67.94 | 68.09 | 66.04 | 63.90 | 61.32 | 57.68 | 51.45 | 48.69 | 47.56 | 47.59 | 51.01 | 54.63 | 58.99 | 62.87 | 60.39 | 59.62 | 56.53 | 52.55 | 54.84 | 54.04 | 52.95 | 51.35 | 50.23 | 49.60 | 49.23 | 50.36 | 51.61 | 51.16 | 55.76 | 58.64 | 63.28 | 65.12 | 63.88 | 63.49 | 63.27 | 62.51 | 62.77 | 59.80 | 56.15 | 53.94 | 50.70 | 49.77 | 46.72 | 46.02 | 41.38 | 41.29 | 40.90 | 38.70 | 40.67 | 40.61 | 41.29 | 40.72 | 41.66 | 40.07 | 38.91 | 39.76 | 39.98 | 39.56 | 38.79 | 37.51 | 36.50 | 36.06 | 34.88 | 8.30 | 8.42 | 9.75 |
Current Ratio |
2.0 | 1.9 | 1.9 | 1.9 | 1.9 | 1.8 | 1.8 | 1.9 | 1.9 | 1.9 | 1.9 | 1.8 | 1.7 | 1.6 | 1.4 | 1.3 | 1.2 | 1.2 | 1.3 | 1.4 | 1.5 | 1.4 | 1.4 | 1.4 | 1.3 | 1.2 | 1.1 | 1.1 | 1.1 | 1.1 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 0.9 | 1.0 | 0.9 | 1.0 | 1.0 | 0.9 | 0.9 | 1.0 | 1.0 | 1.0 | 1.1 | 1.2 | 1.6 | 1.7 | 1.7 | 1.8 | 1.9 | 2.3 | 2.4 | 2.3 | 2.2 | 2.1 | 2.1 | 2.5 | 2.8 | 2.9 | 2.8 | 2.7 | 2.7 |
DSO |
46.7 | 46.1 | 46.2 | 46.8 | 46.5 | 44.7 | 45.7 | 47.1 | 48.9 | 47.3 | 45.6 | 46.1 | 45.6 | 43.9 | 42.9 | 43.4 | 43.4 | 43.2 | 42.0 | 42.4 | 42.7 | 42.2 | 41.8 | 42.3 | 41.6 | 44.4 | 41.5 | 40.5 | 41.8 | 41.7 | 42.0 | 41.3 | 43.0 | 41.2 | 42.0 | 41.7 | 43.4 | 41.7 | 42.5 | 42.1 | 42.4 | 41.5 | 43.8 | 43.3 | 43.8 | 43.7 | 41.6 | 40.5 | 39.1 | 40.8 | 42.8 | 39.9 | 41.9 | 41.2 | 40.8 | 39.9 | 41.7 | 41.9 | 42.7 | 41.0 | 43.1 | 41.2 | 40.2 | - | - | - |
DIO |
79.3 | 80.7 | 83.0 | 81.2 | 84.8 | 86.8 | 94.6 | 91.8 | 92.5 | 91.5 | 94.8 | 94.1 | 98.0 | 96.7 | 96.9 | 96.0 | 93.6 | 83.5 | 77.1 | 69.8 | 67.6 | 63.2 | 64.7 | 62.6 | 68.2 | 77.9 | 69.6 | 66.5 | 70.4 | 67.2 | 67.7 | - | 66.5 | 65.3 | 66.8 | 66.6 | 72.5 | 72.1 | 73.9 | 73.6 | 77.9 | 79.6 | 89.5 | 95.6 | 94.4 | 90.4 | 91.2 | 85.0 | 80.8 | 76.2 | 79.2 | 77.1 | 85.8 | 85.2 | 89.1 | 87.4 | 91.7 | 86.1 | 84.6 | 83.1 | 86.9 | 82.8 | 84.4 | 85.2 | 90.8 | - |
DPO |
28.7 | 27.0 | 26.2 | 24.6 | 25.8 | 26.0 | 20.6 | 19.0 | 27.4 | 27.9 | 21.7 | 20.8 | 27.3 | 27.7 | 22.6 | 22.5 | 32.3 | 32.7 | 25.0 | 20.0 | 24.3 | 24.4 | 19.7 | 17.2 | 22.2 | 26.2 | 19.4 | 19.1 | 25.1 | 24.0 | 20.8 | - | 26.2 | 25.4 | 20.9 | 19.1 | 24.9 | 25.5 | 21.2 | 17.3 | 21.3 | 22.7 | 19.8 | 21.0 | 28.0 | 25.9 | 17.9 | 21.4 | 26.7 | 22.4 | 21.0 | 18.8 | 22.6 | 22.5 | 22.8 | 20.3 | 19.4 | 21.2 | 23.8 | 20.8 | 19.5 | 16.9 | 15.2 | 15.7 | 17.4 | - |
Operating Cycle |
126.0 | - | 129.2 | 128.0 | 131.3 | 131.5 | 140.4 | 138.9 | 141.4 | 138.8 | 140.4 | 140.2 | 143.5 | 140.6 | 139.8 | 139.4 | 137.1 | 126.7 | 119.1 | 112.3 | 110.3 | 105.5 | 106.6 | 105.0 | 109.8 | 122.3 | 111.0 | 107.0 | 112.2 | 109.0 | 109.7 | 41.3 | 107.6 | 106.6 | 108.8 | 108.3 | 116.0 | 113.9 | 116.4 | 115.8 | 120.3 | 121.1 | 133.2 | 138.9 | 138.2 | 134.1 | 132.8 | 125.6 | 120.0 | 116.9 | 122.0 | 117.0 | 127.7 | 126.3 | 129.9 | 127.4 | 133.4 | 128.0 | 127.3 | 124.2 | 130.0 | 124.0 | 124.6 | 85.2 | 90.8 | - |
Cash Conversion Cycle |
97.3 | - | 103.0 | 103.4 | 105.5 | 105.5 | 111.9 | 119.9 | 114.0 | 110.9 | 112.4 | 119.3 | 116.2 | 112.9 | 117.2 | 116.9 | 104.7 | 94.0 | 94.1 | 92.3 | 86.0 | 81.0 | 86.8 | 87.7 | 87.5 | 96.1 | 91.6 | 87.9 | 87.1 | 85.0 | 88.9 | 41.3 | 81.1 | 81.1 | 87.8 | 89.2 | 91.0 | 88.4 | 95.1 | 98.4 | 99.0 | 98.4 | 113.4 | 117.9 | 110.2 | 108.2 | 114.9 | 104.2 | 93.2 | 94.5 | 101.0 | 98.2 | 105.1 | 103.9 | 107.1 | 107.1 | 114.1 | 106.7 | 103.5 | 103.4 | 110.5 | 107.1 | 109.4 | 69.4 | 73.5 | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Multiples are an important financial analysis tool for the company IDEXX Laboratories, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Diagnostics research industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Enzo Biochem
ENZ
|
- | -8.98 % | $ 14.8 K | ||
|
Chembio Diagnostics
CEMI
|
- | 0.22 % | $ 16.8 M | ||
|
Renalytix AI plc
RNLX
|
- | 5.66 % | $ 22.7 M | ||
|
Meridian Bioscience
VIVO
|
- | - | $ 1.49 B | ||
|
Heska Corporation
HSKA
|
- | - | $ 1.31 B | ||
|
Accelerate Diagnostics
AXDX
|
- | -61.36 % | $ 2.46 M | ||
|
T2 Biosystems
TTOO
|
- | -39.35 % | $ 313 K | ||
|
Syneos Health
SYNH
|
- | - | $ 4.46 B | ||
|
Biocept
BIOC
|
- | -13.05 % | $ 7.29 M | ||
|
Invitae Corporation
NVTA
|
- | - | $ 21.2 M | ||
|
Quotient Limited
QTNT
|
- | -11.32 % | $ 1.1 M | ||
|
Brainsway Ltd.
BWAY
|
$ 8.53 | -2.29 % | $ 290 M | ||
|
Burning Rock Biotech Limited
BNR
|
$ 13.46 | 1.05 % | $ 142 M | ||
|
Medpace Holdings
MEDP
|
$ 609.81 | -3.81 % | $ 17.6 B | ||
|
DermTech
DMTK
|
- | -11.32 % | $ 2.94 M | ||
|
Surmodics
SRDX
|
- | - | $ 608 M | ||
|
RadNet
RDNT
|
$ 69.77 | 0.37 % | $ 5.25 B | ||
|
Akumin
AKU
|
- | -17.87 % | $ 25.9 M | ||
|
Psychemedics Corporation
PMD
|
- | -1.84 % | $ 15.3 M | ||
|
Motus GI Holdings
MOTS
|
- | -34.28 % | $ 263 K | ||
|
Biodesix
BDSX
|
$ 7.55 | -9.1 % | $ 57 M | ||
|
HTG Molecular Diagnostics
HTGM
|
- | -20.0 % | $ 1.06 M | ||
|
Agilent Technologies
A
|
$ 169.82 | -3.21 % | $ 48.2 B | ||
|
Charles River Laboratories International
CRL
|
$ 314.38 | -4.13 % | $ 15.6 B | ||
|
Quest Diagnostics Incorporated
DGX
|
$ 257.78 | -0.4 % | $ 28.6 B | ||
|
Danaher Corporation
DHR
|
$ 220.3 | -3.19 % | $ 157 B | ||
|
DexCom
DXCM
|
$ 79.02 | -1.46 % | $ 30.8 B | ||
|
Anixa Biosciences
ANIX
|
$ 2.44 | -6.15 % | $ 79.2 K | ||
|
Celcuity
CELC
|
$ 53.32 | -5.31 % | $ 2.49 B | ||
|
Guardant Health
GH
|
$ 145.9 | 0.21 % | $ 18.3 B | ||
|
BioNano Genomics
BNGO
|
$ 0.82 | -7.56 % | $ 4.46 M | ||
|
Bioventus
BVS
|
$ 9.89 | -0.65 % | $ 659 M | ||
|
IQVIA Holdings
IQV
|
$ 245.67 | -1.92 % | $ 42.2 B | ||
|
Laboratory Corporation of America Holdings
LH
|
$ 367.68 | -0.44 % | $ 30.6 B | ||
|
Castle Biosciences
CSTL
|
$ 32.69 | -2.14 % | $ 948 M | ||
|
Mettler-Toledo International
MTD
|
$ 1 667.59 | -2.3 % | $ 34.4 B | ||
|
Illumina
ILMN
|
$ 192.79 | -3.92 % | $ 29.9 B | ||
|
Natera
NTRA
|
$ 273.11 | -5.8 % | $ 37.3 B | ||
|
Koninklijke Philips N.V.
PHG
|
$ 28.63 | -2.22 % | $ 27.1 B | ||
|
Fulgent Genetics
FLGT
|
$ 24.03 | -3.03 % | $ 740 M | ||
|
CareDx, Inc
CDNA
|
$ 69.9 | -2.81 % | $ 3.72 B | ||
|
Oxford Immunotec Global PLC
OXFD
|
- | - | $ 562 M | ||
|
Biomerica
BMRA
|
$ 1.09 | -0.46 % | $ 3.18 M | ||
|
Interpace Biosciences
IDXG
|
$ 4.4 | -4.35 % | $ 19.5 M | ||
|
Lantheus Holdings
LNTH
|
$ 102.12 | 0.01 % | $ 6.89 B | ||
|
Senseonics Holdings
SENS
|
$ 8.03 | -9.88 % | $ 335 M | ||
|
Sotera Health Company
SHC
|
$ 15.92 | -1.82 % | $ 4.52 B | ||
|
Fluidigm Corporation
FLDM
|
- | 1.08 % | $ 308 M | ||
|
ICON Public Limited Company
ICLR
|
$ 186.79 | -1.88 % | $ 14.6 B |